{
    "body": "List drugs included in the DHAP-R chemotherapy regiment.", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/22136378", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20709662", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21947824", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19406729", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12478903", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23692856", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20660832", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23233612", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16702182", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21656329", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17971487"
    ], 
    "ideal_answer": [
        "Dexamethasone (a steroid hormone), cytarabine (ara-C), cisplatin (platinum agent) and rituximab are included in the DHAP-R chemotherapy protocol."
    ], 
    "exact_answer": [
        [
            "dexamethasone"
        ], 
        [
            "cytarabine"
        ], 
        [
            "cisplatin"
        ], 
        [
            "rituximab"
        ]
    ], 
    "type": "list", 
    "id": "54f0920f94afd61504000018", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 341, 
            "text": "Standard treatment of transplant-eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL) consists of rituximab and platinum-based chemotherapy, either ifosfamide, carboplatin, and etoposide (ICE) or dexamethasone, cytarabine, and cisplatin (DHAP), with autologous transplant consolidation for those with chemosensitive disease.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23692856", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 412, 
            "offsetInEndSection": 698, 
            "text": "The intergroup Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) set the limits for this standard of treatment after first comparing 2 salvage regimens: rituximab, ifosfamide, etoposide, and carboplatin (R-ICE) and rituximab, dexamethasone, aracytine, and cisplatin (R-DHAP). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23233612", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 501, 
            "offsetInEndSection": 810, 
            "text": "The response rate (RR) to first salvage chemotherapy was 23% (RR by regimen: dexamethasone, cytosine arabinoside and cisplatin [DHAP] 15%, etoposide, Solu-Medrol, cytosine arabinoside and cisplatin [ESHAP] 36%, and gemcitabine, dexamethasone and cisplatin [GDP] 45%); 25% (n = 28) of patients underwent ASCT. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22136378", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 449, 
            "text": "PURPOSE: To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21947824", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 339, 
            "text": "The aim of this study was to evaluate the efficacy and toxicity of two chemotherapy regimens based on platinum and cytarabine in association with etoposide and methylprednisolone (ESHAP) or with dexamethasone (DHAP) with or without Rituximab (\u00b1 R) in patients with refractory or a relapsed Primary Central Nervous System Lymphoma (PCNSL). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21656329", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 234, 
            "offsetInEndSection": 307, 
            "text": "R-DHAP combines rituximab with cisplatin, cytarabine, and dexamethasone. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20709662", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 277, 
            "offsetInEndSection": 557, 
            "text": "PATIENTS AND METHODS: Patients with CD20(+) DLBCL in first relapse or who were refractory after first-line therapy were randomly assigned to either rituximab, ifosfamide, etoposide, and carboplatin (R-ICE) or rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20660832", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 487, 
            "offsetInEndSection": 759, 
            "text": "Because of the inability to safely administer unattenuated doses of anthracycline-based regimens, dexamethasone, high-dose cytarabine, and cisplatin (DHAP) was used at full doses (along with rituximab for the DLBCL patient) until hepatic function normalized (1-5 cycles). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19406729", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 176, 
            "offsetInEndSection": 471, 
            "text": "Randomized to DHAP (cisplatin-cytarabine-dexamethasone)-VIM (etoposide-ifosfamide-methotrexate)-DHAP (cisplatin-cytarabine-dexamethasone) chemotherapy with rituximab (R; R-DHAP arm) were 119 patients (113 evaluable) and to chemotherapy without rituximab (DHAP arm) 120 patients (112 evaluable). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17971487", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 220, 
            "offsetInEndSection": 393, 
            "text": "Patients are first randomised between ICE (ifosfamide, carboplatin, etoposide) and DHAP (dexamethasone, ara-C and cisplatin), both combined with rituximab (R-ICE or R-DHAP).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16702182", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 276, 
            "text": "BACKGROUND AND OBJECTIVE: The treatment of the patients with relapsed and refractory non-Hodgkin's lymphoma(NHL) remains difficult. It was reported that DHAP regimen(cisplatin + Ara-C + dexamthsone) was an effective salvage therapy, but there was no report about it in China. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12478903", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 176, 
            "offsetInEndSection": 470, 
            "text": "Randomized to DHAP (cisplatin-cytarabine-dexamethasone)-VIM (etoposide-ifosfamide-methotrexate)-DHAP (cisplatin-cytarabine-dexamethasone) chemotherapy with rituximab (R; R-DHAP arm) were 119 patients (113 evaluable) and to chemotherapy without rituximab (DHAP arm) 120 patients (112 evaluable).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17971487", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 176, 
            "offsetInEndSection": 469, 
            "text": "Randomized to DHAP (cisplatin-cytarabine-dexamethasone)-VIM (etoposide-ifosfamide-methotrexate)-DHAP (cisplatin-cytarabine-dexamethasone) chemotherapy with rituximab (R; R-DHAP arm) were 119 patients (113 evaluable) and to chemotherapy without rituximab (DHAP arm) 120 patients (112 evaluable)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17971487", 
            "endSection": "abstract"
        }
    ]
}